I think you are only the second person who has said that it was not too optimistic to look at our potential as I have. I am more certain that the demand may be there for lenz, once we have an EUA and the results become more broadly known, than I am certain of our ability to produce the tens of millions of treatments that may be demanded. On the one hand, with 3.25B vaccines having been dosed, why can't we produce significantly more than 100k treatments, consisting of 1.8M vials? Or why can't we meet the needs of the 1.4M patients next year who Durrant thinks may meet our patient profile, exclusive of national stockpiles and continents and countries outside of the US and Europe?
News 
Market Data 
Discover 
AI
